Category Archives: Strategy

M&As: Past, Present, and Future

Pharmaceutical Technology’s Faiz Kermani looks at the long history of pharma mergers and finds no sign of the trend slowing down. It was suggested that in one week of April the total value of various rumored deals was of the order of US$100 billion, illustrating how cash-rich major pharmaceutical companies are. Many of the larger […]
Also posted in Deals, Emerging Markets, Europe, Global, Guest Blog, R&D | Tagged , , | Leave a comment

Brown University’s Executive Masters in Healthcare Leadership: A Mission to Transform

Mid-career students at Brown University’s new Executive Masters in Healthcare Leadership program are challenging the status quo with workplace projects focused on one thing: removing the organizational silos that slow innovations in the delivery and financing of healthcare. As the US healthcare system stumbles toward a new consensus built around the “triple aim” of increased […]
Posted in Strategy | Tagged , , | Leave a comment

Emerging Pharma Leader: Joerg Ahlgrimm, Baxter BioScience

By the middle of 2015, global healthcare giant Baxter International Inc. is expected to officially split off its BioScience business, establishing the unit as an independent, innovation-focused biotechnology company. Helming the operational component of these pursuits will be Joerg Ahlgrimm, 41, the division’s current vice president of operations and global supply chain. Ahlgrimm was appointed […]
Also posted in leadership | Tagged , , | Leave a comment

Medtech: Employment Up, Industry “Picking Up Steam”

Medtech employment remained steady in last year with most medical device makers experiencing an increase in their workforce, according to a new jobs report published by EP Vantage. Of the top 15 device makers, only three experienced a reduction in headcount and two of those were due to companies spinning off their respective pharmaceutical operations, […]
Also posted in Deals, Technology | Tagged , , , , , | Leave a comment

Lilly and BI Close In On Diabetes Market Lead

With the recent approval of Jardiance in the US, Eli Lilly and partner Boehringer Ingelheim (BI) “have taken another step towards owning the most comprehensive diabetes portfolio in the industry”, according to research and consulting firm GlobalData.
Posted in Strategy | Tagged , , , , | Leave a comment
  • Categories

  • Meta